Pridopidine, a sigma-1 receptor agonist was shown to increase brain-derived neurotrophic factor (BDNF) levels, reduce mutant huntingtin protein aggregation, and reduce motor impairments in an HD mouse model [369]. This evidence concerns the gene HTT and Huntington disease.